Author Archive: Sougato Das

Sougato Das

Sougato Das is the Director of Partnering Products & Services at BIO. He leads the 25-person team that made partnering possible at BIO 2014, and is responsible for the evolution of partnering at BIO. Previously he was the product manager of CI, clinical intelligence and regulatory products at Thomson Reuters. Prior to that he was a consultant at Parexel, Siemens Medical, IMS Health, Sanofi, Glaxosmithkline, Merck and J&J. He also served as a speaker, instructor and editor at the Drug Information Association. Sougato holds a Masters in Information Science and a Bachelors in Electrical Engineering from the Pennsylvania State University.

Latest Posts

Partnering in Latin America, According to the Experts

LatinAmerica_205x100_Thumbnail copy

Latin America is a hotbed for biotech activity. I recently sat down with four movers and shakers in Latin American biotech to get their thoughts and perspectives: Alexandre Boggio, Director, Business Development, Sanofi Pharma Brazil Carolina Tremmel, Director, New Business Development, Daiichi Sankyo Brasil Edurdo Tsuru, Director, Business Development Latin America, Mundipharma Thiago Mares Guia, MD, PhD, Medical and Scientific Manager, Bionovis See the interview on YouTube: Biotech in Latin America is growing: The Latin Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Partnering Trends in Latin America

BIO-One-On-One

If phonetics were the only driver, BRIC would be CRIB. But life sciences drug-related deal-making and partnering growth in Brazil and the rest of Latin America provide good reason to put the “B” in front. Traditional partnerships (i.e. excluding M&A and early venture funding) where a Latin American company served as the ‘seller’ or ‘out-licensor’ doubled per year from 2009/2010 to 2012. While there was a pullback in 2013, overall growth from 2009/2010 to 2013 Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

What Do Large Pharma and Biotech Companies Want to Buy?

BIO-Partnering-115x76

Out-licensors are always asking this fundamental question: what do in-licensors want? “In-licensors” extend far beyond the top 50 companies. At BIO 2013, there were about 1000 drug R&D companies. Approximately 20% were in-licensors and 80% were out-licensors, according to their BIO One-on-One Partnering profiles. According to Thomson Reuters Recap, there were  a little over 700 licensing and joint venture deals in 2013, involving about 500 buy-siders/licensees. For more on buy-side deal trends, see our recorded webinar with Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO Partnering Q&A: Intersection of Academic and Industry

BIO-One-On-One

Earlier this month, BIO hosted a Google Hangout to discuss BIO Partnering: Intersection of Academic and Industry. We had an excellent lineup of guests discussing emerging models in tech transfer and translational research, novel collaborations between industry and academia, and of course the pivotal role that BIO’s 1-on-1 Partnering and tech transfer programming at #BIO14 will play in advancing industry-university relationships. Since we didn’t get a chance to address all of the excellent questions that Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

BIO Partnering: Intersection of Academic and Industry

BIO-One-On-One

Earlier this month, BIO hosted a Google Hangout to discuss BIO Partnering: Intersection of Academic and Industry. We had an excellent lineup of guests discussing emerging models in tech transfer and translational research, novel collaborations between industry and academia, and of course the pivotal role that BIO’s 1-on-1 Partnering and tech transfer programming at #BIO14 will play in advancing industry-university relationships. Since we didn’t get a chance to address all of the excellent questions that were submitted during Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,